Giovanni Stropoli is an experienced commercial manager in the pharmaceutical industry. Up to January 2015, he served as Senior Vice President for the ‘Mid-Sized Countries’ region at lnterMune, a US-based orphan drug corporation recently acquired by F. Hoffmann-La Roche. While at lnterMune, he successfully launched Esbriet® (pirfenidone) in 11 countries.
Prior to this, he held several roles within Eisai, a large Japanese multinational corporation, from 2005 to 2011, including Country Manager for Italy, Regional Manager for Mid-Sized Countries and finally Senior Vice President, New Markets in London, UK. He was previously Country Manager for Italy at ALK-Abelló, a Danish market leader in vaccine therapy for allergies and he also covered several sales and marketing positions at Eli Lilly, a US-based corporation, with assignments in Italy, the USA and Spain. Giovanni started his professional career in 1998 as a sales representative for the Italian company, Alfa Wassermann. He holds a degree in veterinary medicine.